综述评论 世界临床药物 WORLD CLINICAL DRUGS Vol, 40 NO. 1 ductal adenocarcinoma -associated fibroblasts promotes ell proliferation and apoptosis in prostate cancer cells[JI metastasis J]. PLoS O 13,8(8):e71978-c71978 Gene,2015,572(2):252-258 13] Zhang J, Zhang C, Hu L, et al. Abnormal expression of [24] Amini-Farsani Z, Sangtarash MH, Shamsara M, et al miR-21 and miR-95 in cancer stem-like cells is associated with MiR-221/222 promote chemoresistance to cisplatin in radioresistance of lung cancer []. Cancer Invest, 2015. 33(5) ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway [J]. Cytotechnology, 2018, 70(1): 203-213 14] Najafi Z, Sharifi M G. Degradation of miR-21 [25] Xu Q, Li P, Chen X, et al. miR-221/222 induces pancreatic apoptosis and inhibits cell proliferation in human hepatoc cancer progression through the regulation of matrix carcinoma []. Cancer Gene Ther, 2015. 22(11): 530-535 metalloproteinases[J]. Oncotarget, 2015, 6(16): 14153-14164 5]Xu L, Huang Y, Chen D, et al. Downregulation of miR-21 [26] Sarkar S, Dubaybo H, Ali S, et al. Down-regulation of miR-221 increases cisplatin sensitivity of non-small-cell lung cancer[J inhibits proliferation of pancreatic cancer cells through up- Cancer genet,2014,207(5):214-20 regulation of PTEN, p27kipl, p57kip 2, and PUMAD]. Am J 16] Moriyama T, Ohuchida K, Mizumoto K, et al. MicroRNA-21 Cancer res,2013,3(5):465-477 modulates biological functions of pancreatic cancer cells 27] Zhao L, Zou D, Wei X, et al. MiRNA-221-3p desensitizes including their proliferation, invasion, and chemoresistance [J] pancreatic cancer cells to 5-fluorouracil by targeting RBI[J] lol Cancer Ther,2009,8(5):1067-1074 Tumor biology,2016,37(12):16053-16063 17] Zhao Y, Zhao L, Ischenko 1, et al. Antisense inhibition of 28] Faneca H. Passadouro M. Pedroso De Lima M. MicroRNA microRNA-21 and microRNA-22l in tumor-initiating stem-like modulation combined with sunitinib as a novel therapeutic ells modulates tumorigenesis, metastasis, and chemotherapy strategy for pancreatic cancer [J]. Int J Nanomedicine, 2014, 9: resistance in pancreatic cancer [J]. Target Oncol, 2015, 10(4) 3203-3217 [29] Wong MYW, Yu Y, Walsh WR, et al. microRNA-34 family 18] Hwang JH, Voortman J Giovannetti E, et al. Identification of and treatment of cancers with mutant or wild-type p53 microRNA-21 as a biomarker for chemoresistance and clinical (Review)[]. Int J Oncol, 2011. 38(5): 1189-1195 outcome following adjuvant therapy in resectable pancreatic [30] Vogt M, Munding J, Gruner M, et al. Frequent concomitant cancer[J]. PLoS One, 2010. 5(5) e10630 inactivation of miR-34a and mir-34b/e by CpG methylation in 19] Wang P, Zhuang L, Zhang J, et al. The serum miR-21 olorectal, pancreatic, mammary, ovarian, urothelial, and renal level serves as a predictor for the chemosensitivity of ell carcinomas and soft tissue sarcomas [J]. Virchows Arch, advanced pancreatic cancer, and miR-21 expression confers 201l,458(3):313-322. moresistance by targeting FasL[J]. Mol Oncol, 2013, 7(3) [31] Jafari N, Abediankenari S. MicroRNA-34 dysregulation in 4 gastric cancer and gastric cancer stem cell []. Tumor Bio 20] Dong J, Zhao Y, Zhou L, et al. Bcl-2 upregulation induced by 017,39(5):568835531-568835531 miR-21 via a direct interaction is associated with apoptosis and [32] Zeng Z, Chen X, Zhu D, et al. Low expression of circulating chemoresistance in MIA PaCa-2 pancreatic cancer cells[J MicToRNA-34c is associated with poor prognosis in triple- Arch Med Res, 2011, 42(1): 8-14 negative breast cancer[J]. Yonsei Med J, 2017, 58(4) 21] Song W, Wang L, Huang W, et al. MiR-21 upregulation 697-702 induced by promoter zone histone acetylation is associated [33] Stahlhut C, Slack FJ Combinatorial action of MicroRNAslet-7 with chemoresistance to gemcitabine and enhanced malignancy and miR-34 effectively synergizes with erlotinib to suppress of pancreatic cancer cells[J]. Asian Pac J Cancer Prev, 2013 non-small cell lung cancer cell proliferation[J]. Cell Cycle 14(12):7529-7536. 015,14(13):2171 22] Dentelli P, Traversa M, Rosso A, et al. miR-221/222 control [34] B, et al. Circulating microRNA-34 luminal breast cancer tumor progression by regulating different family low expression correlates with poor prognosis targets[]. Cell Cele,2014,13(11):181l-1826 patients with non-small cell lung cancer[J]. J Thorac Dis 23] Wang L, Liu C, Li C, et al. Effects of microRNA-221/222 on 2017,9(10):3735-3746662019 Vol.40 No.1 世界临床药物 WORLD CLINICAL DRUGS Vol.40 NO.1 66 综述评论 ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis[J]. PLoS One, 2013, 8(8): e71978-e71978. [13] Zhang J, Zhang C, Hu L, et al. Abnormal expression of miR-21 and miR-95 in cancer stem-like cells is associated with radioresistance of lung cancer[J]. Cancer Invest, 2015, 33(5): 165-171. [14] Najafi Z, Sharifi M, Javadi G. Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma[J]. Cancer Gene Ther, 2015, 22(11): 530-535. [15] Xu L, Huang Y, Chen D, et al. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer[J]. Cancer Genet, 2014, 207(5): 214-220. [16] Moriyama T, Ohuchida K, Mizumoto K, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance[J]. Mol Cancer Ther, 2009, 8(5): 1067-1074. [17] Zhao Y, Zhao L, Ischenko I, et al. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer[J]. Target Oncol, 2015, 10(4): 535-548. [18] Hwang JH, Voortman J, Giovannetti E, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer[J]. PLoS One, 2010, 5(5): e10630. [19] Wang P, Zhuang L, Zhang J, et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL[J]. Mol Oncol, 2013, 7(3): 334-345. [20] Dong J, Zhao Y, Zhou L, et al. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells[J]. Arch Med Res, 2011, 42(1): 8-14. [21] Song W, Wang L, Huang W, et al. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells[J]. Asian Pac J Cancer Prev, 2013, 14(12): 7529-7536. [22] Dentelli P, Traversa M, Rosso A, et al. miR-221/222 control luminal breast cancer tumor progression by regulating different targets[J]. Cell Cycle, 2014, 13(11): 1811-1826. [23] Wang L, Liu C, Li C, et al. Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells[J]. Gene, 2015, 572(2): 252-258. [24] Amini-Farsani Z, Sangtarash MH, Shamsara M, et al. MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway[J]. Cytotechnology, 2018, 70(1): 203-213. [25] Xu Q, Li P, Chen X, et al. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases[J]. Oncotarget, 2015, 6(16): 14153-14164. [26] Sarkar S, Dubaybo H, Ali S, et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up￾regulation of PTEN, p27kip1, p57kip2, and PUMA[J]. Am J Cancer Res, 2013, 3(5): 465-477. [27] Zhao L, Zou D, Wei X, et al. MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1[J]. Tumor Biology, 2016, 37(12): 16053-16063. [28] Faneca H, Passadouro M, Pedroso De Lima M. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer[J]. Int J Nanomedicine, 2014, 9: 3203-3217. [29] Wong MYW, Yu Y, Walsh WR, et al. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review)[J]. Int J Oncol, 2011, 38(5): 1189-1195. [30] Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas[J]. Virchows Arch, 2011, 458(3): 313-322. [31] Jafari N, Abediankenari S. MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell[J]. Tumor Biol, 2017, 39(5): 568835531-568835531. [32] Zeng Z, Chen X, Zhu D, et al. Low expression of circulating MicroRNA-34c is associated with poor prognosis in triple￾negative breast cancer[J]. Yonsei Med J, 2017, 58(4): 697-702. [33] Stahlhut C, Slack FJ. Combinatorial action of MicroRNAslet-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation[J]. Cell Cycle, 2015, 14(13): 2171-2180. [34] Zhao K, Cheng J, Chen B, et al. Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer[J]. J Thorac Dis, 2017, 9(10): 3735-3746